Advanced search×

Risk management of nanomaterials.

Audio, Transactions of the IRE Professional... 2(2):130-7 (2010) PMID 20077523

Nanotechnology has become the focus of a large amount of scientific, political, and financial interest. Limited information on the exposure to nanomaterials is available, with only a few occupational exposure studies having been performed. While laboratory animal studies on the biological effects of some nanomaterials have been published, no epidemiological studies have been reported to date. This lack of data on exposure and human health effects hinders risk assessment of these materials. As the use of nanomaterials increases rapidly, it is of vital importance that the risk assessment community understands the complexities of the issues surrounding the manufacture, use and disposal of nanomaterials, the potential of environmental and occupational exposure to human populations, as well as adverse health outcomes. For this to happen, it is in many ways necessary for the scientific community to also understand what questions risk assessors need to ask, and what research will best answer them. Risk management of nanomaterials requires more information as to the human and ecological effects of exposure to various nanomaterials. At this time, there are no specific regulations for nanomaterials, but a few efforts to include nanomaterials under existing environmental regulations have begun. The purpose of this article is to describe the potential regulations for nanomaterials, and the current issues related to the risk assessment of nanomaterials.

DOI: 10.1002/wnan.57
Version: za2963e q8za3 q8zb6 q8zc1 q8zdf q8ze1 q8zfd q8zg0

Similar articles you may find interesting…

  1. Imaging of apoptosis in the heart with nanoparticle technology.

    Wiley Interdiscip Rev RNA 3(1):86-99 (2011) PMID 20945336

  2. Genetic basis for congenital heart defects: current knowledge: a scientific statement from the American Heart Association Congenital Cardiac...

    Circulation 115(23):3015-38 (2007) PMID 17519398

    The intent of this review is to provide the clinician with a summary of what is currently known about the contribution of genetics to the origin of congenital heart disease. Techniques are discussed to evaluate children with heart disease for genetic alterations. Many of these techniques are now ava...
  3. Molecular MRI detects low levels of cardiomyocyte apoptosis in a transgenic model of chronic heart failure.

    Circ Cardiovasc Imaging 2(6):468-75 (2009) PMID 19920045

    We thus aimed to develop a platform to image CM apoptosis quantitatively and specifically in heart failure in vivo. The myocardium in heart failure, however, is characterized by very low levels of CM apoptosis and normal vascular permeability, factors thought to preclude the use of molecular MRI....